Clinical Trials Logo

Effect of Drugs clinical trials

View clinical trials related to Effect of Drugs.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04326504 Recruiting - HIV Infections Clinical Trials

Dolutegravir and Clinical Outcomes Among ART-recipients in Brazil

CODE
Start date: February 1, 2021
Phase:
Study type: Observational [Patient Registry]

Access to antiretroviral therapy (ART) in low-income and middle-income countries has been scaled-up effectively over recent years. Recently, the World Health Organization (WHO) guidelines changed to recommend the use of Dolutegravir (DTG) combined with two nucleoside reverse transcriptase inhibitors (NRTIs), tenofovir and lamivudine, for first-line ART; however, there is still a need for further data on the outcomes of DTG-based regimens for people with HIV-1. This study aims to describe the outcomes of drug-naïve and experienced patients starting a dolutegravir (DTG)-based regimen in a large cohort of HIV - infected patients in Brazil and compare to outcomes obtained from a retrospective control group of subjects who initiated non-DTG-based ART.

NCT ID: NCT04042597 Recruiting - Quality of Life Clinical Trials

Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma

CSSG-03
Start date: July 18, 2019
Phase: Phase 2
Study type: Interventional

For local relapse not amenable to reasonable curative surgery or for those with metastatic chordoma, chemotherapy is recognised as inactive. The major study drug is the small molecular tyrosine kinase inhibitors targeted at the stem cell factor receptor (KIT) and the platelet-derived growth factor receptors (PDGFRA and PDGFRB), eg. imatinib. Anlotinib is a novel tyrosine kinase inhibitor targeting both at VEGFR-2, -3 and PDGFRA and PDGFRB with high affinity, which also showed broad antitumor activity against EGFR and so on. Thus this multicenter, two-armed phase II trial of PKUPH-sarcoma 05 intended to investigate the efficacy and safety of anlotinib versus imatinib on advanced chordoma.

NCT ID: NCT03791372 Recruiting - Safety Issues Clinical Trials

Clinical Effect and Safety of Autologous Umbilical Cord Blood Transfusion in the Treatment of Cerebral Palsy

Start date: October 10, 2017
Phase: Phase 1
Study type: Interventional

To study the clinical efficacy and safety of autologous umbilical cord blood transfusion in the treatment of cerebral palsy.

NCT ID: NCT03700177 Recruiting - Anesthesia, Local Clinical Trials

Ropivacaine 0,2% Plus Dexamethasone Versus Ropivacaine 0,2% Plus Placebo in Modified Pectoral Block

Start date: February 1, 2019
Phase: Phase 4
Study type: Interventional

To find out if dexamethasone used as adjuvant to ropivacaine, a long-lasting local anesthetic, prolongs the duration of modified pectoral nerve block in women undergoing breast surgery.

NCT ID: NCT03120273 Recruiting - Safety Issues Clinical Trials

A Clinical Trial to Evaluate the Safety and Tolerability of Dexlansoprazole Injection in Healthy Chinese Adults(Part 2)

Start date: May 5, 2017
Phase: Phase 1
Study type: Interventional

This is a single center, open-label, multiple-dose phase 1 clinical trial. This study will determine the pharmacokinetics (PK), pharmacodynamics (PD), safety and side-effect profile of an investigational dexlansoprazole injection after multiple intravenous administration in healthy Chinese adults.

NCT ID: NCT03053076 Recruiting - Safety Issues Clinical Trials

Safety and Efficacy of Autologous Umbilical Cord Blood Mononuclear Cells Transfusion in Neonates

Start date: February 10, 2017
Phase: Phase 1
Study type: Interventional

To study the safety and efficacy of Autologous Umbilical Cord Blood Mononuclear Cells transfusion on clinical outcome in preterm infants